Home  |  About SITC  |   Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

iSBTc 25th Annual Meeting

October 2 - 4, 2010                                                                       
Hyatt Regency Washington on Capitol Hill
Washington, D.C.

25th Annual Meeting Webinar

Program Schedule
To view slides from a presenter click the icon next to the presentation title.

Friday, October 1
8:00 am - 5:00 pm Workshop on Monoclonal Antibodies in Cancer
For more information, click here.
8:00 am - 5:00 pm Primer on Tumor Immunology and Biological Therapy of Cancer
For more information, please click here.
 
Saturday, October 2
7:50 am - 8:00 am President's Welcome
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
8:00 am - 8:45 am Richard V. Smalley, MD Memorial Lectureship
Presentation SlidesImmune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities

James P. Allison, PhD - Memorial Sloan-Kettering Cancer Center
8:45 am - 11:30 am



8:45 am - 9:15 am


9:15 am - 9:45 am



9:45 am - 10:00 am



10:30 am - 10:45 am



10:45 am - 11:00 am



11:00 am - 11:30 am
Plenary Session:  Dendritic Cells and Cancer
Co-Chairs:     Carl G. Figdor, PhD - Nijmegen Centre for Molecular Life Sciences
                         Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute

Dendritic Cell Vaccination in Cancer: Achievements, Obstacles and Future Perspectives
Carl G. Figdor, PhD - Nijmegen Centre for Molecular Life Sciences

Progress in the Active Immunotherapy of Prostate Cancer: Sipuleucel-T, an Autologous
Cellular Immunotherapy

David L. Urdal, PhD - Dendreon Corporation

Presentation Slides Therapeutic Vaccination with Autologous mRNA Electroporated Dendritic Cells in Patients
with Advanced Melanoma

Bart Neyns, MD, PhD - Universitair Ziekenhuis Brussel

Presentation Slides Resistance to the Proapoptotic Effects of IFN-γ on Melanoma Cells Used in Patient-Specific
Dendritic Cell Immunotherapy is Associated with Improved Overall Survival

Andrew N. Cornforth, PhD - Hoag Memorial Hospital Cancer Center

Presentation Slides IFN-gamma is Central to Both Immunogenic and Tolerogenic Properties of Dendritic Cells
After IL-12 and GM-CSF Microsphere Treatment

Jamie L. Harden - State University of New York, University at Buffalo

Polarized Dendritic Cells in the Immunotherapy of Established Cancer: Roles of Signal 3 and
Signal 4

Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
1:30 pm - 3:00 pm



1:30 pm - 2:00 pm


2:00 pm - 2:30 pm


2:30 pm  - 2:45 pm


2:45 pm - 3:00 pm
Concurrent Session I:  Targeted Therapeutics and Immunotherapy
Co-Chairs:     Mary L. Disis, MD - University of Washington
                      Keiran S. Smalley, PhD - H. Lee Moffitt Cancer & Research Institute

Immune Modulation of Breast Cancer
Mary L. Disis, MD - University of Washington

Overcoming BRAF Inhibitor Resistance in Melanoma
Keiran S. Smalley, PhD - H. Lee Moffitt Cancer & Research Institute

Presentation Slides The High-Dose Aldesleukin (IL-2) "Select" Trail in Patients with Metastatic Renal Cell
Carcinoma

Kim A. Margolin, MD - Seattle Cancer Care Alliance

In Vivo Modeling and Detection of Ovarian Cancer Vascular Marker TEM1
Chunsheng Li, PhD - Ovarian Cancer Research Center, University of Pennsylvania
1:30 pm - 3:00 pm



1:30 pm - 2:00 pm


2:00 pm - 2:15 pm


2:15 pm - 2:30 pm



2:30 pm - 3:00 pm
Concurrent Session II: Innate / Adaptive Immune Interplay in Cancer
Co-Chairs:    Vincenzo Cerundolo, MD, PhD - University of Oxford - Institute of Molecular Medicine
                      Laurence Zitvogel, MD, PhD - Institute Gustave Roussy

Presentation Slides The Role of Invariant NKT Cells at the Interface of Innate and Adaptive Immunity
Vincenzo Cerundolo, MD, PhD - University of Oxford - Institute of Molecular Medicine

Presentation Slides T-Regulatory Cells in Colon Cancer: Friend or Foe?
Khashayarsha Khazaie, PhD, DSc - Northwestern University, Robert Lurie Comprehensive Cancer Ctr.

Myeloid-Derived Suppressor Cells and Decreased Interferon Responsiveness in
Tumor-Bearing Mice

Bethany Mundy - The Ohio State University

The Desirable Cell Death for Chemotherapy of Cancer
Laurence Zitvogel, MD, PhD - Institute Gustave Roussy
3:15 pm - 5:15 pm



3:15 pm - 3:35 pm


3:35 pm - 3:55 pm


3:55 pm - 4:15 pm


4:15 pm - 4:35 pm


4:35 pm - 5:15 pm
Plenary Session:  Clinical Trial Endpoints
Co-Chairs:   F. Stephen Hodi, MD - Dana-Farber Cancer Institute
                     
Vernon K. Sondak, MD - H. Lee Moffitt Cancer

Presentation Slides Decoding the Tower of Babel
Vernon K. Sondak, MD - H. Lee Moffitt Cancer & Research Center

Immune-Related Response Criteria - Finding Missed Signals of Activity for Immunotherapy
F. Stephen Hodi, MD - Dana-Farber Cancer Institute

Presentation Slides Defining Response in Prostate Cancer Immunotherapy
Lawrence Fong, MD - University of California - San Francisco

Moving Beyond Tumor Size: A New Paradigm in Cancer Imaging
Annick Van den Abbeele, MD - Dana-Farber Cancer Institute

Panel Discussion
5:15 pm - 5:45 pm Presentation Slides Clinical Immunotherapy Guidelines: A New iSBTc Initiative
Howard L. Kaufman, MD - Rush University Medical Center
5:45 pm - 6:15 pm iSBTc Membership Business Meeting
   
Sunday, October 3
8:00 am - 8:45 am Keynote Address
Presentation Slides Therapeutic vaccination against HPV16-induced disease

Cornelius J.M. Melief, MD, PhD - Leiden University Medical Center
8:45 am - 11:30 am



8:45 am - 9:15 am


9:15 am - 9:45 am



9:45 am - 10:00 am




10:30 am - 11:00 am


11:00 am - 11:15 am




11:15 am - 11:30 am
Plenary Session:  Vaccine Combinations
Co-Chairs:     Pierre Coulie, MD, PhD - de Duve Institute and University of Louvain
                      Victor H. Engelhard, PhD - University of Virginia School of Medicine

Numbers and Functions of Lymphocytes in Human Melanoma Metastases
Pierre Coulie, MD, PhD - de Duve Institute and University of Louvain

Phosphopeptides Presented by MHC Class I and Class II Molecules: A New Category of Tumor Associated Antigens with Immunotherapeutic Potential
Victor H. Engelhard, PhD - University of Virginia School of Medicine

Presentation Slides Induction of CD8+ T Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations with α-Type-1-Polarized Dendritic Cells and Poly-ICLC in Patients with Recurrent Malignant Glioma
Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute

Presentation Slides Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Jedd D. Wolchok, MD, PhD - Memorial Sloan-Kettering Cancer Center

T Cell Activation, PSMA Seroconversion and Increased Th17 Rates are Associated with Favorable Clinical Outcome in Prostate Cancer Patients Treated with Prostate GVAX and Anti-CTLA-4 Immunotherapy
Saskia J. Santegoets, PhD - VU University Medical Center

Presentation Slides Vaccine Sites as Sinks and Graveyards for Tumor-specific T Cells
Willem W. Overwijk, PhD - University of Texas, MD Anderson Cancer Center
11:30 am - 11:45 am Presentation Slides Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma
Antoni Ribas, MD - University of California, Los Angeles
1:30 pm - 2:50 pm


1:30 pm - 1:50 pm



1:50 pm - 2:10 pm



2:10 pm - 2:30 pm



2:30pm - 2:50 PM
Presidential Abstract Session
Chair:             Bernard A. Fox, PhD - Earle A. Chiles Research Institute

Interferon-β Secretion in the Tumor Microenvironment can Cause Potent Tumor Control Through Host Cells Independently from Adaptive Immunity
Robbert Spaapen, PhD - University of Chicago

4-1BB Activation Induces the Master-Regulator EOMES and a Broad-Spectrum TH1 Phenotype which Synergizes with CTLA-4 Blockade to Reject B16 Melanoma
Michael A. Curran, PhD - Memorial Sloan-Kettering Cancer Center

Ovarian Cancer Cells Ubiquitously Express HER-2 and can be Distinguished from Normal Ovary by Genetically Redirected T Cells
Evripidis Lanitis, BS - University of Pennsylvania

Large-Scale Profiling of Circulating Serum Markers, Single Cell Polyfunctionality and Antigen Diversity of T Cell Response Against Melanoma
Chao Ma, MS - California Institute of Technology
 
3:15 pm - 4:45 pm



3:15 pm - 3:45 pm


3:45 pm - 4:00 pm



4:00 pm - 4:15 pm



4:15 pm - 4:45 pm
Concurrent Session I:  Countering Negative Regulation
Co-Chairs:     Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research
                         Weiping Zou, MD, PhD - University of Michigan

Is it Possible to Correct the Impaired Function of Human Tumor-Infiltrating T Lymphocytes?
Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research

Presentation Slides The Multikinase Inhibitor Sorafenib Reverses the Suppression of IL-12 and Enhancement of IL-10 by PGE2 in Murine Macrophages
Leisha A. Emens, MD, PhD - Johns Hopkins University School of Medicine

Presentation Slides Loss of HLA-DR Expression on CD14+ Cells: A Common Marker of Immunosuppression in Cancer Patients
Michael P. Gustafson, PhD - Mayo Clinic

Inflammatory Tregs in the Human Tumor and Chronic Inflammatory Microenvironments
Weiping Zou, MD, PhD - University of Michigan
3:15 pm - 4:45 pm



3:15 pm - 3:45 pm


3:45 pm - 4:00 pm



4:00 pm - 4:30 pm


4:30 pm - 4:45 pm
Concurrent Session II:  Immune Cell Trafficking to Tumor Microenvironment
Co-Chairs:    Thomas F. Gajewski, MD, PhD - University of Chicago
                        Elizabeth M. Jaffee, MD - Johns Hopkins University

Presentation Slides Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment
Thomas F. Gajewski, MD, PhD - University of Chicago

Spatial and Temporal Regulation of CXCR3 Chemokine Production and CD8 T Cell Infiltration in the Metastatic Melanoma Microenvironment
David W. Mullins, PhD - University of Virginia

Effector/Memory Regulatory T Cells and Their Role in the Tumor Microenvironment
Elizabeth M. Jaffee, MD - Johns Hopkins University

NGR-TNF, A Selective Vessel-Targeting Agent, Increases the Therapeutic Potential of Chemo-Immunotherapy
Arianna Calcinotto - San Raffaele Scientific Institute
5:00 pm - 5:30 pm Presentation Slides Update:  2009 iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer
Lisa H. Butterfield, PhD - University of Pittsburgh
5:30 pm - 6:00 pm Cancer Immunotherapy Trials Network Update
Presentation Slides William Merritt PhD - National Cancer Institute
Presentation Slides Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center
   
Monday, October 4
8:00 am - 10:15 am



8:00 am - 8:30 am



8:30 am - 8:45 am



8:45 am - 9:00 am



9:00 am - 9:30 am


9:30 am - 9:45 am


9:45 am - 10:15 am
Plenary Session:  Adoptive T Cell Transfer: The Next Wave
Co-Chairs:   Patrick Hwu, MD - University of Texas, MD Anderson Cancer Center
                    Ton N. Schumacher, PhD - Netherlands Cancer Institute

Presentation Slides Improving the Efficacy and Safety of G-M Virus-Specific T cells for Solid Tumors
Malcolm K. Brenner, MD, PhD - Baylor College of Medicine

Presentation Slides Functional Reprogramming of the Tumor Stroma by IL-12 Engineered T Cells is Required for Anti-Tumor Immunity
Sid Kerkar, MD - National Cancer institute, Center for Cancer Research, NIH

Presentation Slides Noninvasive Positron Emission Tomography (PET) Imaging of Sleeping Beauty (SB) Modified CD19-Specific T Cells Expressing Herpes Simplex Virus1-Thymidine Kinase
Pallavi Raja Manuri, PhD - University of Texas, MD Anderson Cancer Center

Presentation Slides Dissection of Therapy-Induced Melanoma-Reactive Cytotoxic T Cell Responses
Ton N. Schumacher, PhD - Netherlands Cancer Institute

Presentations Slides Therapeutic Cell Engineering Using Surface-Conjugated Synthetic Nanoparticles
Matthias Stephen, MD, PhD - Massachusetts Institute of Technology

Adoptive T Cell Therapy for Metastatic Melanoma: The MD Anderson Experience
Laszlo G. Radvanyi, PhD - University of Texas, MD Anderson Cancer Center
Patrick Hwu, MD - University of Texas, MD Anderson Cancer Center
   

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.  



Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Meetings  |  Membership  |  Patient/Consumer Resources  |  Professional Resources  |  Support SITC
© 2014 Society for Immunotherapy of Cancer. All rights reserved.